TLRY drops as weak momentum weighs on the stock

Traders Union
All News
Stocks
Tilray slides 4.73% to $4.60 today

Highlights

Tilray Brands has increased its global cultivation capacity to about 275 metric tonnes to address growing international medical cannabis demand.
The expansion strengthens Tilray's ability to meet both regulatory and market requirements in Canada and Europe, supporting long-term growth.
Shares of Tilray stock fell 4.73% to $4.6, with technical indicators mixed and a trading range expected between $4.39 to $4.81 in the coming days.

Production capacity rises as international demand drives expansion

Tilray Brands has expanded its global cannabis cultivation footprint across Canada and Europe, bringing total annual production capacity to around 275 metric tonnes to address increasing demand for international medical cannabis, according to GlobeNewswire. This move increases supply capability and better positions Tilray to meet regulatory and market requirements in its target geographies. While the expansion supports longer-term growth prospects and operational scale, price action has remained under broader selling pressure.

Conflicting momentum and resistance levels cap TLRY's technical rebound

On the technical front, TLRY has moved above its MA-20 but remains constrained below the MA-50 on the hourly chart and the longer-term MA-200, reflecting medium- and long-term resistance levels. The Ichimoku Kijun at $4.62 acts as immediate overhead resistance. Momentum indicators present a mixed picture: MACD currently flashes a buy, but ADX is neutral, and RSI shows a sell, with Stochastic RSI and CCI both confirming a lack of clear overbought or oversold signals. Bearish dominance is highlighted by the intraday Bearish signal from Bull/Bear Power, while the Awesome Oscillator reads neutral, suggesting uncertainty in directional conviction.

Consolidation phase persists as breakout triggers remain absent

In the near term, TLRY is expected to fluctuate within a $4.39 to $4.81 range based on typical volatility. With both bullish and bearish probabilities balanced at 50%, a decisive move is not yet dominant. A bullish breakout scenario would require clearing resistance at $4.62; conversely, a drop below $4.39 could lead to further downside risk, keeping the price action in a consolidation phase until a catalyst emerges.

Viktoras Karapetjanc, expert at Traders Union, sees Tilray’s capacity expansion as a clear signal of management’s confidence in rising global medical cannabis demand. He notes the company is improving its strategic positioning, though current market sentiment remains mixed. Karapetjanc believes macro pressures are still weighing on price action, but fundamentals are turning more favorable. "If Tilray maintains its operational momentum, I expect longer-term investors to benefit once broader market headwinds subside."

Earlier, analysts noted that Tilray was stuck in a consolidation phase with technical signals lacking clear bullish or bearish conviction. The current analysis maintains this neutral stance, with trading likely to remain rangebound between $4.39 and $4.81 until a catalyst prompts a decisive breakout.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.